Neuralstem (CUR) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Neuralstem Reports First Quarter 2015 Financial Results And Provides Business and Clinical Update
May 8, 2015 7:30 AM EDTGERMANTOWN, M.D., May 8, 2015 /PRNewswire/ --Â Neuralstem, Inc. (NYSE MKT: CUR) a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, reported its financial results for the three months ended March 31, 2015 and provided a business and clinical update.
"Neuralstem made substantial clinical progress this quarter in both our cell therapy and small molecule programs. We announced positive top-line safety data and encouraging secondary efficacy data for our Phase II ALS clinical trial, and look forward with anticipation to... More
Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer
May 6, 2015 7:31 AM EDTGERMANTOWN, Md., May 6, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced the appointment of Jonathan Lloyd Jones to the position of Chief Financial Officer, effective May 18th.
Mr. Lloyd Jones brings to the position more than 25 years of corporate finance and business development experience. Â Â Most recently, Mr. Lloyd Jones served as Chief Financial Officer at Columbia Laboratories (Juniper Pharmaceuticals), a Nasdaq-listed biotech company.... More
